About us
Immunicom is one of the most promising biotech start-ups in the immunotherapy space today. We focus on creating novel immunotherapies based on our breakthrough technology platform – Immunopheresis™.
Immunopheresis is designed to address unmet medical needs in cancer, inflammatory, cardiovascular, renal and autoimmune diseases and to be accessible to broad patient populations.
With a strong talent base and financial resources, Immunicom is on an accelerated path to make its therapies widely available via partnerships with leading hospitals around the world.
Key facts
1
Immunicom’s breakthrough blood-filtering immunotherapy device works external to the body and received FDA Breakthrough Device recognition in 2018
2
With an initial focus on immuno-oncology, Immunicom has already secured CE Mark approval for use in adults with advanced, refractory, triple-negative breast cancer in Europe.
3
Immunicom R&D is working from the replicable Immunopheresis platform to create a robust pipeline of immunotherapy treatments.
4
Our clinical team is conducting multiple clinical trials around the world to potentially expand indications to address triple negative breast cancer, resistant metastatic melanoma, renal cell carcinoma and non-small cell lung cancer. Our therapy also has the potential to treat different cancers beyond those listed above.
Our Mission
To improve the quality of life for patients
in a meaningful way and expedite their
path to a healthy future.
VISION
Immunicom reimagines healing
All to often, patients face the challenging decision of sacrificing their quality of life to obtain treatment for serious, life-threatening diseases. Often choosing not to participate in care at all. We believe people should not have to make trade-offs between living fulfilling lives and healing.
We envision a future where no one needs to sacrifice living their life to the fullest in order to receive life-saving treatment.
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team